Exagen Inc. to Participate in the Canaccord Genuity 41st Annual Growth Conference
July 29, 2021 08:25 ET
|
Exagen Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 41st Annual...
Exagen to Announce Second Quarter 2021 Financial Results on August 9, 2021
July 26, 2021 16:06 ET
|
Exagen Inc.
SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2021 after...
Lupus Nephritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Lupus Pipeline Comprising a Broad Spectrum of Molecular Targets
July 19, 2021 20:10 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, July 19, 2021 (GLOBE NEWSWIRE) -- Lupus Nephritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Lupus Pipeline Comprising a Broad Spectrum of Molecular Targets ...
AVISE® Lupus Test Demonstrates Statistically Significant Clinical Utility in Achieving a Definitive SLE Diagnosis and Positively Impacts Treatment Decisions
July 13, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, July 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the publication of their latest clinical utility study in...
Exagen Elects Frank Stokes to Board of Directors
June 18, 2021 08:29 ET
|
Exagen Inc.
SAN DIEGO, June 18, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the company’s stockholders approved the election of...
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
June 17, 2021 07:30 ET
|
Biogen Inc.
Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo, in active systemic lupus erythematosus (SLE), a debilitating autoimmune disease which has limited...
Exagen Inc. to Participate in the William Blair 41st Annual Growth Stock Conference
May 24, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 41st Annual Growth...
Exagen Inc. Reports First Quarter 2021 Results
May 11, 2021 16:05 ET
|
Exagen Inc.
Quarterly Records: AVISE® CTD Volumes, Ordering Healthcare Providers and Adopters SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...
Exagen Inc., Allegheny Health Network Research Institute and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests
May 04, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, Allegheny Health Network (AHN) Research Institute and the AHN Autoimmunity...
Exagen Announces New Campaign and Initiatives for Lupus Awareness Month
May 03, 2021 08:25 ET
|
Exagen Inc.
SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of...